All In MedTech

Device Trial Radar · NCT05378386

ALTERRA Post-Approval Study

Multicenter Post-Approval Study of Congenital Pulmonic Valve Dysfunction Studying the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System With Alterra Adaptive Prestent

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

150

Actual

Start

May 12, 2022

Primary completion

Sep 25, 2025

Study completion Jul 2035

Sponsor

Lead sponsor
Edwards LifesciencesPublic (EW)
Sponsor type
Industry
First posted
May 18, 2022

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will monitor device performance and outcomes in subjects undergoing implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent in the post-approval setting

Conditions

  • Pulmonary Valve Insufficiency
  • Complex Congenital Heart Defect
  • Tetralogy of Fallot
  • Pulmonary Regurgitation
  • RVOT Anomaly

Interventions

  • Edwards Alterra Adaptive Prestent with SAPIEN 3 Transcatheter Pulmonary Valve SystemDevice

    The Edwards Alterra Adaptive Prestent is designed to reduce the diameter of large irregular right ventricular outflow tracts (RVOTs) and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 transcatheter heart valve (THV).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Acute Device SuccessTime frame: 24 hours post-procedure

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • Children's of Alabama

    Birmingham, Alabama

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Cedars Sinai Medical Center

    Los Angeles, California

21 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.